Parvus Therapeutics

Parvus Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called Navacims™ to treat and potentially cure autoimmune diseases. The company's proprietary platform uses peptide-MHC-coated nanoparticles to induce the endogenous generation of disease-specific regulatory T cells (Tregs). These Tregs restore immune tolerance by suppressing autoimmune attacks on specific organs without compromising the patient's overall immune system. Founded on the research of Dr. Pere Santamaria at the University of Calgary, Parvus is advancing a robust pipeline targeting high-unmet-need indications including liver diseases, inflammatory bowel disease (IBD), and Type 1 Diabetes. The company has secured major strategic partnerships with industry leaders like AbbVie and Genentech to accelerate the development of its nanomedicine platform.